Noxopharm Limited
Noxopharm Limited
Your view on NOX.AX
Overview
What the company does, where it operates, and who runs it.
About Noxopharm Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Olivier Laczka
- Headquarters
- 60 Linksley Avenue, Glenhaven, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Olivier Laczka
- Headquarters
- 60 Linksley Avenue, Glenhaven, NSW, AU
Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers.
Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer.
The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries.
Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma.
Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Noxopharm Limited. Starting points for Noxopharm Limited: EPS -AUD 0.02, beta 0.00 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Noxopharm Limited. Noxopharm Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Noxopharm Limited. Trailing twelve-month EPS for Noxopharm Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Noxopharm Limited. Noxopharm Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| BDX.AXBCAL Diagnostics Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| HMD.AXHeraMED Limited | Healthcare | Medical - Devices | — | ||
| IDT.AXIDT Australia Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| IMC.AXImmuron Limited | Healthcare | Biotechnology | — | ||
| NC6.AXNanollose Limited | Healthcare | Biotechnology | — | ||
| OSL.AXOncoSil Medical Ltd | Healthcare | Medical - Devices | — | ||
| PAB.AXPatrys Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ONCYOncolytics Biotech Inc. | Healthcare | NASDAQ | $44.2M | ||
| ONPHOncology Pharma Inc. | Healthcare | OTC | $109,553 | ||
| ONTTFOxford Nanopore Technologies plc | Healthcare | OTC | $1.8B | ||
| OPORFhVIVO plc | Healthcare | OTC | $59.2M | ||
| ORGSOrgenesis Inc. | Healthcare | OTC | $3.0M | ||
| ORICORIC Pharmaceuticals, Inc. | Healthcare | NASDAQ | $795.1M | ||
| ORKAOruka Therapeutics, Inc. | Healthcare | NASDAQ | $6.5B | ||
| ORMPOramed Pharmaceuticals Inc. | Healthcare | NASDAQ | $169.2M | ||
| ORPOFOSE Immunotherapeutics S.A. | Healthcare | OTC | $260.3M | ||
| ORYZFOryzon Genomics S.A. | Healthcare | OTC | $283.9M | ||
| OSRHWOSR Holdings, Inc. | Healthcare | NASDAQ | $7.8M | ||
| OSTXOS Therapies Incorporated | Healthcare | AMEX | $48.1M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Noxopharm Limited.